Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioMed X Launches New T Cell Immunology Discovery Platform
Details : A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for T Cell Therapy and immunology discovery.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Merck to support up to six more research groups at the BioMed X Institute in Heidelberg within the next six years in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2021
Reset All
